Dr. Jameel Abdulrehman, a hematologist at the University of Toronto, dives into the intricate world of venous thromboembolism (VTE) management. He discusses the latest CHEST Guidelines and compares direct oral anticoagulants to traditional therapies like warfarin. The conversation highlights risk assessment strategies, emphasizing gender-specific responses to anticoagulation. Abdulrehman also sheds light on extended anticoagulation for cancer-related thrombosis and managing superficial vein thrombosis, showcasing the complexities of treatment decisions.
Direct oral anticoagulants like Rivaroxaban and Apixaban are preferred for VTE management due to their efficacy and convenience over warfarin.
The management of subsegmental pulmonary embolism may involve observation and careful monitoring rather than immediate anticoagulation, depending on individual patient risk factors.
Deep dives
Introduction to Freed AI Medical Scribe
Freed is an advanced AI medical scribe designed to assist clinicians by automating the transcription and generation of clinical notes in their personal style. It caters to various specialties, functioning seamlessly during both in-office and virtual visits, and supports multiple languages. This tool not only enhances efficiency but also ensures compliance with HIPAA regulations, thereby maintaining patient confidentiality. With Freed, clinicians can potentially save up to two hours daily, enabling them to focus more on patient care rather than documentation tasks.
Management of Antithrombotic Therapy for VTE
Direct oral anticoagulants (DOACs) have largely supplanted vitamin K antagonists like warfarin for managing venous thromboembolism (VTE) due to their lower risk of major bleeding and convenience since they do not require routine monitoring. Although DOACs are favored, specific cases may necessitate the use of VKAs, such as when drug interactions, severe renal impairment, or cost is a consideration. Among the DOACs, Rivaroxaban and Apixaban are frequently preferred, with Rivaroxaban offering once-daily dosing compared to the twice-daily Apixaban. Current guidelines recommend evaluating the risk versus benefit of continuing anticoagulation after the initial treatment period, particularly for those with unprovoked VTE who may have higher recurrence rates.
Guidelines for Management of Subsegmental Pulmonary Embolism
The management of subsegmental pulmonary embolism (PE) remains a complex issue, with recent guidelines suggesting observation rather than immediate anticoagulation under certain circumstances. New evidence indicates that these small PEs may carry a risk of recurrence, especially in younger patients or those with additional comorbidities. If a patient presents with a subsegmental PE but has no detectable DVT, the approach may involve close monitoring and regular ultrasounds to assess for progression. The CHESS guidelines emphasize individualized treatment strategies based on risk factors, ultimately guiding clinicians in deciding whether anticoagulation is necessary.
In this episiode, Dr. Sheliza Halani interview Dr. Jameel Abdulrehman (Hematology, Thrombosis) about the latest recommendations in the CHEST 2021 Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report
Host: Dr. Sheliza Halani Guest: Dr. Jameel Abdulrehman, Hematologist, Assistant Professor at University of Toronto Sound Editing: Alison Lai
Do you ever feel like you can't get ahead of charting? Freed AI has an AI driven scribe for you! You can try Freed for free right now by going to getfreed.ai. Listeners can use the INTERN50 code for $50 off their first month!